Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Illumina ( (ILMN) ) has shared an announcement.
In the first quarter of fiscal 2026, reported on April 30, 2026, Illumina posted revenue of $1.09 billion, up 4.8% year over year, with GAAP operating margin rising to 19.2% and GAAP diluted EPS increasing to $0.87. Strong operating cash flow and higher margins, alongside robust demand for NovaSeq X, underpinned management’s decision to lift full-year 2026 revenue and non-GAAP EPS guidance.
On April 28, 2026, the board authorized a new $1.5 billion share repurchase program, in addition to the August 2024 authorization that still had $314 million of capacity remaining. The expanded buyback capacity, combined with improved profitability metrics and raised outlook, highlights Illumina’s confidence in its cash generation and its strategy to return capital to shareholders while strengthening its market position in genomic sequencing.
The most recent analyst rating on (ILMN) stock is a Sell with a $110.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Neutral.
The score is driven primarily by the TTM financial turnaround and strong cash generation, reinforced by constructive 2026 guidance and clinical/NovaSeq X momentum. Offsetting factors include elevated leverage and prior-year earnings volatility, plus mixed technical signals and notable near-term headwinds (China/export restrictions, research softness, tariffs, and SomaLogic dilution).
To see Spark’s full report on ILMN stock, click here.
More about Illumina
Illumina, Inc., based in San Diego, operates in the genomics and life-sciences industry, providing sequencing platforms, related instruments, and consumables for clinical and research customers worldwide. The company’s ecosystem, including its NovaSeq X platform, targets growing demand for high-throughput sequencing and emerging application areas in clinical genomics and proteomics.
In the first quarter of fiscal 2026, reported on April 30, 2026, Illumina posted revenue of $1.09 billion, up 4.8% year over year, with GAAP operating margin rising to 19.2% and GAAP diluted EPS increasing to $0.87. The board authorized a new $1.5 billion share repurchase program on April 28, 2026, supplementing an existing program, while strong cash generation and demand for NovaSeq X led management to raise full-year 2026 revenue and non-GAAP EPS guidance, signaling confidence in near-term growth and shareholder returns.
Average Trading Volume: 1,825,429
Technical Sentiment Signal: Sell
Current Market Cap: $18.29B
Learn more about ILMN stock on TipRanks’ Stock Analysis page.